Richard K. Prins
Known title: DirectorCIK: 0001047579
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused. IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.
Transaction History
| AMPH | ▼ Sell | Open Market | 7,973 | $162K | 8/11/2026 | View on chart |
| AMPH | ▲ Buy | Grant | 8,143 | $0 | 6/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 70,000 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 1/19/2026 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 4,179 | $70K | 11/25/2025 | View on chart |
| AMPH | ▼ Sell | Open Market | 4,179 | $113K | 11/25/2025 | View on chart |
| AMPH | ▲ Buy | Grant | 5,122 | $0 | 6/2/2025 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 10,000 | $195K | 12/9/2024 | View on chart |
| AMPH | ▼ Sell | Open Market | 10,000 | $438K | 12/9/2024 | View on chart |
| AMPH | ▼ Sell | Gift | 410 | $0 | 12/9/2024 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 2,500 | $42K | 11/12/2024 | View on chart |
| AMPH | ▼ Sell | Open Market | 5,000 | $244K | 11/12/2024 | View on chart |
| AMPH | ▼ Sell | Gift | 1,000 | $0 | 11/12/2024 | View on chart |
| AMPH | ▼ Sell | Gift | 1,500 | $0 | 8/19/2024 | View on chart |
| IGC | ▼ Sell | Gift | 200,000 | $0 | 8/12/2024 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 7,182 | $140K | 8/12/2024 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 3,915 | $78K | 8/12/2024 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 6,004 | $121K | 8/12/2024 | View on chart |
| AMPH | ▼ Sell | Open Market | 17,101 | $737K | 8/12/2024 | View on chart |
| AMPH | ▲ Buy | Grant | 3,076 | $0 | 6/3/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 58,333 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 42,750 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 28,500 | $0 | 3/13/2024 | View on chart |
| AMPH | ▼ Sell | Open Market | 4,000 | $223K | 11/17/2023 | View on chart |
| AMPH | ▼ Sell | Gift | 1,000 | $0 | 11/17/2023 | View on chart |
| AMPH | ▼ Sell | Open Market | 5,000 | $263K | 11/13/2023 | View on chart |
| AMPH | ▼ Sell | Open Market | 2,000 | $105K | 8/18/2023 | View on chart |
| AMPH | ▼ Sell | Open Market | 4,163 | $239K | 8/15/2023 | View on chart |
| AMPH | ▲ Buy | Grant | 2,716 | $0 | 6/5/2023 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 5,000 | $83K | 5/15/2023 | View on chart |
| AMPH | ▼ Sell | Open Market | 5,000 | $218K | 5/15/2023 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 5,000 | $83K | 5/12/2023 | View on chart |
| AMPH | ▼ Sell | Open Market | 5,000 | $210K | 5/12/2023 | View on chart |
| AMPH | ▼ Sell | Gift | 3,000 | $0 | 5/12/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 58,334 | $0 | 3/31/2023 | View on chart |
| AMPH | ▲ Buy | Grant | 4,163 | $0 | 6/10/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 31,250 | $0 | 6/1/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 93,750 | $0 | 5/31/2022 | View on chart |
| AMPH | ▼ Sell | Gift | 2,000 | $0 | 5/17/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 3/21/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 10,000 | $171K | 3/15/2022 | View on chart |
| AMPH | ▼ Sell | Open Market | 10,000 | $340K | 3/15/2022 | View on chart |
| IGC | ▼ Sell | Gift | 40,000 | $0 | 12/23/2021 | View on chart |
| IGC | ▲ Buy | Grant | 300,000 | $0 | 12/20/2021 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 5,291 | $91K | 12/10/2021 | View on chart |
| AMPH | ▼ Sell | Open Market | 5,291 | $113K | 12/10/2021 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 5,000 | $86K | 11/22/2021 | View on chart |
| AMPH | ▼ Sell | Open Market | 5,000 | $106K | 11/22/2021 | View on chart |
| IGC | ▲ Buy | Grant | 300,000 | $0 | 5/13/2021 | View on chart |
| IGC | ▼ Sell | Open Market | 50,000 | $88K | 3/9/2021 | View on chart |
| IGC | ▼ Sell | Open Market | 500 | $905 | 3/3/2021 | View on chart |
| IGC | ▼ Sell | Open Market | 49,500 | $89K | 3/3/2021 | View on chart |
| IGC | ▼ Sell | Gift | 25,000 | $0 | 2/10/2021 | View on chart |
| IGC | ▼ Sell | Open Market | 50,000 | $102K | 12/1/2020 | View on chart |
| IGC | ▼ Sell | Gift | 20,000 | $0 | 11/9/2020 | View on chart |
| IGC | ▼ Sell | Gift | 13,000 | $0 | 10/13/2020 | View on chart |
| IGC | ▼ Sell | Gift | 60,000 | $0 | 8/13/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis
A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis. A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.